ABSTRACT
Biologic treatments are increasingly being used in the management of moderate to severe plaque psoriasis (PSO). Risankizumab (RZB) is a humanized monoclonal antibody that specifically blocks the p19 subunit of interleukin 23, which in turn regulates the activation, differentiation, and survival of Th17. RZB has proved their efficacy and their safety compared to anti-TNF. However, studies that assess and compare the improvement in other secondary PROs such as the patient's quality of life are still scarce. Health-related quality of life (HRQoL) is the sum of physical health, well-being, and participation; it defines the functional effect of a disease or its treatment and how it is perceived by the patient. The objective of this paper is to analyze the literature on the impact of treatment with RZB on the quality of life of patients with PSO and their psychological well-being. A bibliographic search was carried out to identify all the papers published from July 2015 to June 1, 2022, on RZB treatment in psoriasis and its impact on health-related quality of life and psychological well-being, finally twenty articles have been evaluated in full text, of which 8 were excluded because they did not meet the inclusion criteria. Risankizumab has shown not only to have very relevant data on effectiveness and safety, but all of this is associated with an improvement in quality of life related to health and psychological well-being measured on generic and specific quality of life scales, both in pivotal trials, ad hoc analysis, and data in real clinical practice.
ABSTRACT
After the beginning of the SARS-CoV-2 pandemic, our dermatology department created a multidisciplinary unit to manage patients with cutaneous manifestations associated with COVID-19. With the objective of identifying skin lesions in patients with suspected COVID-19 and evaluating possible associations with systemic involvement, other infectious agents and coagulation disorders, we carried out a prospective observational study that included all patients that attended our COVID-19 dermatology clinic with a multidisciplinary protocol. A total of 63 patients (mean 34.6 years) were enrolled between May 2020 and February 2021. Overall, 27 patients (42.9%) had a positive COVID-19 test, and 74.6% had COVID-19 clinical signs. The most common skin lesion was maculopapular rash (36.5%), predominantly seen in male (54.2%) and older patients (42 vs. 30 years), followed by chilblain-like lesions (20.6%) in younger patients (13.9 vs. 20.9 years) who were predominantly barefoot at home (69.2%); these patients exhibited a tendency towards a negative COVID-19 test. A total of 12 patients (19.1%) had positive serology for herpesvirus 6 (IgM or IgG). We conclude that the COVID-19-associated skin lesions we observed were similar to those previously described. Questions as to the underlying mechanisms remain. Interferon, possibly aided by cold exposure, may cause perniosis-like lesions. Other cutaneous manifestations were similar to those caused by other viruses, suggesting that SARS-CoV-2 may reactivate or facilitate other viral infections.
Subject(s)
Aminolevulinic Acid/analogs & derivatives , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Leishmaniasis, Mucocutaneous/drug therapy , Photochemotherapy , Photosensitizing Agents/administration & dosage , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab/therapeutic use , Aminolevulinic Acid/administration & dosage , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/immunology , Female , Humans , Immunocompromised Host , Leishmaniasis, Mucocutaneous/complications , Leishmaniasis, Mucocutaneous/pathology , Methotrexate/therapeutic use , Middle Aged , Skin Cream , Treatment OutcomeSubject(s)
Dermatitis, Allergic Contact/etiology , Mycosis Fungoides/pathology , Skin Neoplasms/pathology , Tuberculin/adverse effects , Allergens/adverse effects , Allergens/pharmacology , Biopsy, Needle , Dermatitis, Allergic Contact/pathology , Diagnosis, Differential , Follow-Up Studies , Humans , Immunohistochemistry , Latex Hypersensitivity/diagnosis , Male , Middle Aged , Mycosis Fungoides/diagnosis , Patch Tests , Risk Assessment , Skin Neoplasms/diagnosisABSTRACT
We report the case of a patient with a black and turquoise tattoo who developed sarcoid granulomas on the areas of black pigment. Patch tests showed a positive reaction to nickel, cobalt, and cadmium; spectrophotometric analysis of the black pigment revealed the presence of nickel and cobalt among other metals. Although the pathogenesis of sarcoid granulomas is unknown, it seems that a delayed type hypersensitivity reaction is one of the mechanisms involved.